4.7 Article

Pentamethylquercetin ameliorates fibrosis in diabetic Goto-Kakizaki rat kidneys and mesangial cells with suppression of TGF-β/Smads signaling

Journal

EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 713, Issue 1-3, Pages 6-15

Publisher

ELSEVIER
DOI: 10.1016/j.ejphar.2013.04.045

Keywords

Pentamethylquercetin; Diabetic nephropathy; Renal fibrosis; Goto-Kakizaki Rats; Mesangial cell; TGF-beta/Smads signaling

Funding

  1. National Natural Science Foundation of China [30772575, 81273563]
  2. National Mega Project on Major Drug Development [2011ZX09401-302]

Ask authors/readers for more resources

Pentamethylquercetin (PMQ) has been shown to possess glucose-lowering properties, but its effect on renal fibrosis in diabetes is still unclear. This study was designed to investigate the effect of PMQ on renal fibrosis and the underlying mechanisms in spontaneous type II diabetic Goto-Kakizaki rats and mesangial cells in high glucose. We found that in Goto-Kakizaki rats, PMQ treatment attenuated glomerular volume, glycogen deposition, renal collagen and fibronectin accumulation, in addition to amelioration of diabetic symptoms, including reduction of urine volume and urine glucose levels. In mesangial cells, PMQ remarkably inhibited the cell proliferation and total collagen accumulation, and suppressed cell hypertrophy. Further experiments showed that PMQ treatment down-regulated the expression of TGF-beta(1), up-regulated Smad7 and inhibited Smad2/3 activation in vivo and vitro. Our results demonstrated that PMQ ameliorated renal fibrosis in diabetes, which may be associated with suppressed TGF-beta/Smads signaling. (c) 2013 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available